News

News

/
/
News
InxMed Announced the Completion of RMB 130M (~US$ 19M) Series A+ Financing to Accelerate Its Clinical Development and Strengthen Translational Capabilities
InxMed Announced the Completion of RMB  130M (~US$ 19M) Series A+ Financing to Accelerate Its Clinical Development and Strengthen Translational Capabilities
Interview of Zaiqi Wang – Chairman & CEO, InxMed by PharmaBoardroom
Interview of Zaiqi Wang – Chairman & CEO, InxMed by PharmaBoardroom
Dr Zaiqi Wang, chairman and CEO of Chinese oncology biotech InxMed, highlights the vital importance of combination therapies in cancer treatment, assesses the level of innovation in China, and outlines his strategy for the company moving forward.
See more information
Dr Zaiqi Wang, chairman and CEO of Chinese oncology biotech InxMed, highlights the vital importance of combination therapies in cancer treatment, assesses the level of innovation in China, and outlines his strategy for the company moving forward.
InxMed Released Research Data of “FAK inhibitor IN10018 overcomes drug resistance of KRAS G12C inhibition” at 2020 AACR Annual Meeting
InxMed Released Research Data of “FAK inhibitor IN10018 overcomes drug resistance of KRAS G12C inhibition” at 2020 AACR Annual Meeting
SHANGHAI, June 24, 2020 -- InxMed (Shanghai) Co., Ltd. ("InxMed" or "Company"), a clinical stage biotech company dedicated to developing innovative, individualized medicines with international impact,
See more information
SHANGHAI, June 24, 2020 -- InxMed (Shanghai) Co., Ltd. ("InxMed" or "Company"), a clinical stage biotech company dedicated to developing innovative, individualized medicines with international impact,
InxMed Announces Dosing of First Patient in a Phase Ib Trial of IN10018 as Monotherapy and Combination Therapy in Patients with Uveal Melanoma and NRAS mutant Metastatic Melanoma in the United States
InxMed Announces Dosing of First Patient in a Phase Ib Trial of IN10018 as Monotherapy and Combination Therapy in Patients with Uveal Melanoma and NRAS mutant Metastatic Melanoma in the United States
Shanghai, China—InxMed (Shanghai) Co., Ltd.(“InxMed” or “Company”), a clinical stage biotech company dedicated to developing innovative, individualized medicines with international impact, announced today that the company has dosed first patient in its Phase Ib clinical trial of IN10018 as monotherapy and in combination with MEKi in the patients either with metastatic uveal melanoma or NRAS mutant metastatic melanoma at The University of Texas M. D. Anderson Cancer Center, United States.
See more information
Shanghai, China—InxMed (Shanghai) Co., Ltd.(“InxMed” or “Company”), a clinical stage biotech company dedicated to developing innovative, individualized medicines with international impact, announced today that the company has dosed first patient in its Phase Ib clinical trial of IN10018 as monotherapy and in combination with MEKi in the patients either with metastatic uveal melanoma or NRAS mutant metastatic melanoma at The University of Texas M. D. Anderson Cancer Center, United States.
InxMed Announces Clinical Collaboration with MSD to Evaluate IN10018 in Combination with Pembrolizumab January 07, 2020
InxMed Announces Clinical Collaboration with MSD to Evaluate IN10018 in Combination with Pembrolizumab   January 07, 2020
Shanghai, China – InxMed (Shanghai) Co., Ltd., a clinical stage biotech company dedicated to developing innovative, individualized medicines with international impact, today announced that the company
See more information
Shanghai, China – InxMed (Shanghai) Co., Ltd., a clinical stage biotech company dedicated to developing innovative, individualized medicines with international impact, today announced that the company
InxMed Receives Approval to Initiate Phase I Clinical Trial in China for IN10018
InxMed Receives Approval to Initiate Phase I Clinical Trial in China for IN10018
Shanghai, China—InxMed (Shanghai) Co., Ltd.(“InxMed” or “Company”), a clinical stage biotech company dedicated to developing innovative, individualized medicines with international impact, announced today that the Company has obtained IND (Investigational New Drug) clearance for IN10018, a proprietary focal adhesion kinase (FAK) inhibitor, from China National Medical Products Administration (NMPA) to initiate Phase I clinical trial in patients with locally advanced or metastatic gastric cancer. Previously IN10018 has opened IND in the United States in August 2019.
See more information
Shanghai, China—InxMed (Shanghai) Co., Ltd.(“InxMed” or “Company”), a clinical stage biotech company dedicated to developing innovative, individualized medicines with international impact, announced today that the Company has obtained IND (Investigational New Drug) clearance for IN10018, a proprietary focal adhesion kinase (FAK) inhibitor, from China National Medical Products Administration (NMPA) to initiate Phase I clinical trial in patients with locally advanced or metastatic gastric cancer. Previously IN10018 has opened IND in the United States in August 2019.
InxMed Announces Clinical Collaboration to Evaluate IN10018 in Combination with Cobimetinib
InxMed Announces Clinical Collaboration to Evaluate IN10018 in Combination with Cobimetinib
Shanghai, China – InxMed (Shanghai) Co., Ltd., (“InxMed” or “Company”) today announced that the company has entered into a clinical collaboration with Roche (F. Hoffmann-La Roche Ltd.,) to evaluate IN10018, a proprietary focal adhesion kinase (FAK) inhibitor in combination with Roche’s Cobimetinib, an inhibitor of mitogen-activated protein kinase (MEK).
See more information
Shanghai, China – InxMed (Shanghai) Co., Ltd., (“InxMed” or “Company”) today announced that the company has entered into a clinical collaboration with Roche (F. Hoffmann-La Roche Ltd.,) to evaluate IN10018, a proprietary focal adhesion kinase (FAK) inhibitor in combination with Roche’s Cobimetinib, an inhibitor of mitogen-activated protein kinase (MEK).
InxMed Receives US FDA IND Approval to Initiate Clinical Trial for IN10018
InxMed Receives US FDA IND Approval to Initiate Clinical Trial for IN10018
Shanghai, China—InxMed (Shanghai) Co., Ltd. (“InxMed” or “Company”), announced that the Company has obtained FDA (Food and Drug Administration) IND clearance for IN10018, a proprietary focal adhesion kinase (FAK) inhibitor. This is InxMed's first IND opening approved by FDA, which reflects the company's superior R&D capability.
See more information
Shanghai, China—InxMed (Shanghai) Co., Ltd. (“InxMed” or “Company”), announced that the Company has obtained FDA (Food and Drug Administration) IND clearance for IN10018, a proprietary focal adhesion kinase (FAK) inhibitor. This is InxMed's first IND opening approved by FDA, which reflects the company's superior R&D capability.
Previous page
1
2
InxMed

Copyright © 2019  InxMed  ICP备10238728号  Powered by 300.cn